Male gender |
17 (50%) |
Median age at study entry, year (range) |
10 (3-17%) |
Underlying disease*
|
|
ALL
|
19 (56%)
|
AML
|
8 (24%)
|
Other†
|
9 (26%)
|
Stem-cell transplantation |
|
Overall
|
13 (38%)
|
Allogeneic
|
13 (38%)
|
Autologous
|
0
|
BMT <6 months before infection
|
10 (29%)
|
Disease status |
|
Remission
|
23 (68%)
|
Non-complete remission
|
11 (32%)
|
Severe neutropenia (ANC<500/mm3)
|
31 (91)
|
Mean duration of neutropenia, days ± SD
|
17 ± 14
|
Risk classification for fungal infection‡
|
|
Standard risk
|
12 (35%)
|
High risk
|
22 (65%)
|
Post-BMT
|
13 (38%)
|
Relapsing leukemia
|
11 (32%)
|
AML
|
8 (24%)
|
High-risk ALL
|
6 (18%)
|
Surgical treatment |
|
No. of ESS, mean (range)
|
3.2 (1-11)
|
Multiple procedures
|
24 (71%)
|
Extrasinus extension
|
11 (33%)
|
PCR detection |
22 (65%) |
Fungal pathogen |
|
Aspergillus
|
20 (59%)
|
Mucormycosis
|
12 (35%)
|
Other
|
20 (59%)
|
Systemic antifungal therapy |
|
Amphotericin B
|
9 (26%)
|
Ambisome
|
13 (38%)
|
Voriconazole
|
11 (32%)
|
Mortality |
|
Overall
|
13 (38%)
|
Dead of infection
|
9 (26%)
|